{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:19:51Z","timestamp":1738819191538,"version":"3.37.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.rmr.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T12:26:50Z","timestamp":1737376010000},"page":"88-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elexacaftor, Tezacaftor et Ivacaftor\u00a0: \u00e9valuation de l\u2019efficacit\u00e9 imm\u00e9diate par spirom\u00e9trie \u00e0 domicile"],"prefix":"10.1016","volume":"42","author":[{"given":"M.","family":"Thimmesch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Boulay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Defgn\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Bauwens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Palem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2025.01.001_bib0090","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3\u00a0trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2025.01.001_bib0095","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2025.01.001_bib0100","doi-asserted-by":"crossref","first-page":"2100185","DOI":"10.1183\/13993003.00185-2021","article-title":"Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration","volume":"59","author":"Morrison","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2025.01.001_bib0105","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","article-title":"Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis","volume":"128","author":"Quittner","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2025.01.001_bib0110","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.201710-1981ST","article-title":"Recommendations for a standardized pulmonary function report. An Official American Thoracic Society Technical Statement","volume":"196","author":"Culver","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2025.01.001_bib0115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2025.01.001_bib0120","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-Gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2025.01.001_bib0125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2025.01.001_bib0130","unstructured":"CFTR1. https:\/\/www.sickkids.on.ca\/. 2011 [accessed 18\u00a0june 2023]."},{"key":"10.1016\/j.rmr.2025.01.001_bib0135","unstructured":"Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf\/. 2021 [accessed 18\u00a0june 2023]."},{"key":"10.1016\/j.rmr.2025.01.001_bib0140","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/jpm11050421","article-title":"Personalized medicine based on nasal epithelial cells: comparative studies with rectal biopsies and intestinal organoids","volume":"11","author":"Silva","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.rmr.2025.01.001_bib0145","doi-asserted-by":"crossref","first-page":"103660","DOI":"10.1016\/j.ebiom.2021.103660","article-title":"Perspectives on the translation of in-vitro studies to precision medicine in cystic fibrosis","volume":"73","author":"Dumas","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.rmr.2025.01.001_bib0150","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.rmr.2025.01.001_bib0155","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/cpt.2425","article-title":"A useful and sustainable role for N-of-1\u00a0trials in the healthcare ecosystem","volume":"112","author":"Selker","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rmr.2025.01.001_bib0160","doi-asserted-by":"crossref","first-page":"2202437","DOI":"10.1183\/13993003.02437-2022","article-title":"The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2025.01.001_bib0165","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1002\/ppul.26147","article-title":"Real-world feasibility of short-term, unsupervised home spirometry in CF","volume":"57","author":"Davis","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.rmr.2025.01.001_bib0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1159\/000334907","article-title":"Accuracy of office spirometry performed by trained primary-care physicians using the MIR Spirobank hand-held spirometer","volume":"83","author":"Degryse","year":"2012","journal-title":"Respiration"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842525000014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842525000014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T12:11:48Z","timestamp":1738757508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842525000014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0761842525000014"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2025.01.001","relation":{},"ISSN":["0761-8425"],"issn-type":[{"type":"print","value":"0761-8425"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor, Tezacaftor et Ivacaftor\u00a0: \u00e9valuation de l\u2019efficacit\u00e9 imm\u00e9diate par spirom\u00e9trie \u00e0 domicile","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS on behalf of SPLF.","name":"copyright","label":"Copyright"}]}}